A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test if pembrolizumab is safe and effective for
treating patients with metastatic high-grade neuroendocrine tumors who have failed platinum
based chemotherapy.The study drug, pembrolizumab has been FDA approved for treating a type of
skin cancer called melanoma and for metastatic non-small cell lung cancer. However, it is not
approved for treatment of metastatic high-grade neuroendocrine tumors.